Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2018 08:00 ET | Source: InspireMD, Inc.

InspireMD Announces Upcoming Presentations at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)

TEL AVIV, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
November 06, 2018 07:00 ET | Source: InspireMD, Inc.

InspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update

Presented Three-Year Data Highlighting Long-Term Safety and Efficacy of CGuard™ Embolic Prevention System On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am...
October 30, 2018 08:00 ET | Source: InspireMD, Inc.

InspireMD to Report Third Quarter 2018 Financial Results and Provide Business Update on Tuesday, November 6

Conference Call Scheduled for 8am Eastern Time TEL AVIV, Israel, Oct. 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS)...
September 27, 2018 09:28 ET | Source: InspireMD, Inc.

InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference

Preliminary Three-Year Data Continue to Show Unprecedented Safety, Efficacy and Durability of Stroke Prevention in Treating Carotid Artery Stenosis TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE)...
September 24, 2018 08:00 ET | Source: InspireMD, Inc.

InspireMD Announces Regulatory Approval of CGuard™ Embolic Prevention System in Mexico

TEL AVIV, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
September 17, 2018 08:00 ET | Source: InspireMD, Inc.

InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet™ Stent Jacket and Related Drug Eluting Technology

Patents further strengthen intellectual property surrounding Company’s lead commercial product, CGuard™ EPS InspireMD remains on track to submit an Investigational Device Exception (IDE) with FDA...
September 04, 2018 07:30 ET | Source: InspireMD, Inc.

InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City

TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
August 06, 2018 16:05 ET | Source: InspireMD, Inc.

InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018

TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
July 31, 2018 07:00 ET | Source: InspireMD, Inc.

InspireMD Schedules Second Quarter 2018 Earnings Conference Call

Tel Aviv, July 31, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid...
July 23, 2018 08:41 ET | Source: InspireMD, Inc.

InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence

Tel Aviv, Israel, July 23, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right